News Image

Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Provided By GlobeNewswire

Last update: Nov 5, 2024

Turnstone’s next-generation Selected TIL technology is designed to selectively expand the most potent tumor-reactive T cells for treatment of solid tumors

Results further support the continued clinical advancement of TIDAL-01, currently being evaluated in Phase 1 trials

Read more at globenewswire.com

TURNSTONE BIOLOGICS CORP

NASDAQ:TSBX (7/28/2025, 4:30:01 PM)

0.3525

-0.01 (-2.08%)



Find more stocks in the Stock Screener

Follow ChartMill for more